Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


15 mayo 2013

Científicos crean células madre humanas a través de clonaciones

Reuters

Después de más de 15 años de fracasos científicos en todo el mundo y un fraude de alto perfil, biólogos en Estados Unidos han creado células madre humanas con la misma técnica que produjo a la famosa oveja Dolly en 1996: trasplantar material genético de una célula adulta en un óvulo cuyo ADN había sido removido.

09 mayo 2013

Statistical Analysis Supports Renal Denervation for Treating Hypertension Across Age Groups

Endovascular Today

The Society of Cardiovascular Angiography and Interventions (SCAI) announced the presentation of data suggesting that catheter-based renal denervation is projected to improve blood pressure and substantially reduce the incidence of major cardiovascular events in patients whose high blood pressure has not been sufficiently lowered with medications. Lead Investigator Jan Pietzsch, PhD, presented the findings at the SCAI 2013 scientific sessions in Orlando, Florida.

09 mayo 2013

Glue a promising tool in the varicose vein occlusion armamentarium

Vascular News

Gerard Stansby, Newcastle, UK, told delegates at CX35 (6–9 April 2013, London, UK) that the use of glue in varicose veins in safe and effective and that, if it continues to show good results, it will be a very attractive procedure for the future.

07 mayo 2013

Radiosurgery treatments for lung cancer using Varian Medical Systems Technologies presented at ESTRO

Interventional News

Detailed experiences of stereotactic ablative body radiotherapy (SABR) treatments using Varian’s TrueBeam medical linear accelerator and Calypso “GPS for the Body” tumour-tracking technology were discussed at the annual European Society for Radiotherapy and Oncology (ESTRO) Forum (19–23 April 2013, Geneva, Switzerland) at the Varian Emerging Technologies Symposium.

18 abril 2013

Examen de antígeno prostático eleva número de procedimientos y riesgos: estudio

Reuters Health

La mayoría de los adultos mayores en Estados Unidos a los que se les diagnosticó un cáncer con el antígeno prostático específico (PSA, por su nombre en inglés) decidió someterse a un tratamiento, aún cuando los signos revelaban una enfermedad de avance muy lento, indicó un reciente estudio.

03 mayo 2013

Cost effective prostate cancer treatment underused in the UK

Interventional News

The study, which was presented at the European Society for Radiotherapy and Oncology (ESTRO) 19 to 23 April 2013, Geneva, Switzerland, used the latest cost effectiveness model to look at relevant recent data for prostate cancer. The study analysed research findings from six recent overview studies, involving 55,000 patients and looked at disease progression, associated costs and outcomes extrapolated over a ten-year time horizon from a UK National Health Service (NHS) cost perspective.

02 mayo 2013

Cook Medical announces CE mark approval for PVA foam embolization particles

Interventional News

Cook Medical, on the 1 May 2013, announced it had received CE mark approval for their PVA foam embolization particles to treat benign prostatic hyperplasia. According to a company release, the PVA foam embolization particles will be shown at the Global Embolization Symposium and Technologies (GEST) 1–4 May 2013 in Prague, Czech Republic.

26 abril 2013

Stenting dramatically improves treatment access for dialysis patients

Interventional News

The RENOVA (Post-approval study for the Flair endovascular stent graft) results showed that stent grafts keep access sites open significantly longer in haemodialysis patients than angioplasty alone, according to a presentation given at the Society of Interventional Radiology’s (SIR) Annual Meeting (13−18 April 2013, New Orleans, USA).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.